In contrast, another study reported poorer two-year survival in NPC patients with a higher percentage of CD56+ cells, as compared to those with lower CD56+ percentage on immunohistochemistry (IHC) [110]. The gene discussed is NCAM1; the disease is nasopharyngeal carcinoma.